



Fresenius Medical Care

P R E S S R E L E A S E

December 22, 2006
Dr. Bernd Ebeling,
Corporate Communications
Tel.: +49-6172-6082378
Fax: +49-6172-6082294
e-mail: pr@fmc-ag.com
www.fmc-ag.com

Fresenius Medical Care donates 150,000 euros to aid dialysis patients

As part of its 10-year anniversary, Fresenius Medical Care, the worldwide dialysis market leader, will donate € 150,000 to charitable organizations that aid dialysis patients. The German National Kidney Association (Bundesverband Niere e.V.) will receive € 50,000 while similar organizations in North America and the Asia-Pacific region will obtain the remaining € 100,000. The Company consciously decided against celebrating the occasion with receptions and parties. The approximately 18,000 members of the German National Kidney Association are dedicated to improving the lives of patients with chronic kidney disease. The Association will use the funds donated by Fresenius Medical Care for its self-help, prevention and information programs as well as to assist those affected by kidney disease.

Fresenius Medical Care looks back on ten years of successful growth. In 1996, Fresenius acquired the largest dialysis clinic operator in the world, National Medical Care, and merged the company with its own dialysis equipment division to create the new company. Fresenius used the opportunity to take a major step into the market for dialysis care. Since then, both revenue and the number of employees have more than doubled, the number of dialysis clinics has more than tripled and the Company was added to Germany's benchmark DAX 30 index in 1999.

Today, Fresenius Medical Care is the leading provider of dialysis services treating about 161,433 patients in its 2,085 own clinics worldwide. Fresenius Medical Care also is the undisputed leader in the dialysis products. When it comes to the two key products for hemodialysis, the Company has created an even wider gap to its competitors – nearly every other new dialysis machine and nearly every other new dialyzer is a Fresenius Medical Care product.

The Company remains on the path for growth. Fresenius Medical Care plans on increasing sales by 2010 to \$ 11.5 billion. This growth will be attained both organically and through attractive acquisitions that further strengthen its network of dialysis clinics. The Company's unique vertical structure will also aid its expansion as its innovative products are combined with its patient care services. Furthermore, a new initiative will create horizontal growth by combining the Company's product technology, its treatment expertise and its abilities as a care provider into new "Pharma-Tech" therapies utilizing proven drugs.

###

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,400,000 individuals worldwide. Through its network of 2,085 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 161,433 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products). Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS-p).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.